100 Participants Needed

Digital Therapeutics for PTSD and Cannabis Use Disorder

(RISE-C Trial)

Recruiting at 5 trial locations
NA
Overseen ByNicole A Short, PhD
Age: 18+
Sex: Female
Trial Phase: Academic
Sponsor: University of Nevada, Las Vegas
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial tests a new digital therapy for women who have experienced sexual assault and are at risk for developing posttraumatic stress disorder (PTSD) and cannabis use disorder (CUD). Participants will use one of two smartphone-based programs: one focused on relaxation breathing exercises (Relaxation Control) and the other on managing anxiety through cognitive techniques (RISE Guide). Women who have recently experienced a sexual assault, use cannabis weekly, and have a smartphone might be a good fit. This research could help develop effective tools to support recovery and reduce reliance on cannabis as a coping mechanism. As an unphased trial, this study offers participants the chance to contribute to innovative research that could lead to new therapeutic options for those in need.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Is there any evidence suggesting that this trial's treatments are likely to be safe?

Research has shown that the RISE Guide, a short program designed to change negative thoughts and behaviors, is generally safe. Such programs are well-known and typically have few side effects.

The Relaxation Control treatment, which uses the Breathe2Relax app for deep breathing exercises, is also considered safe. These exercises are often used to manage stress and anxiety without causing harm.

Currently, no direct evidence from studies indicates any problems or safety issues with these specific treatments. However, both methods—changing thought patterns and relaxation exercises—are commonly used and well-tolerated in many situations, suggesting they are likely safe for participants.12345

Why are researchers excited about this trial?

Researchers are excited about these treatments for PTSD and Cannabis Use Disorder because they offer unique, tech-based approaches. The RISE Guide delivers cognitive behavioral therapy through smartphones, focusing on anxiety sensitivity with tailored, real-time intervention reminders. This makes therapy more accessible and personalized. On the other hand, the Relaxation Control method leverages the "Breathe2Relax" app to teach diaphragm breathing for stress management, which is different from traditional medication-based treatments. These digital solutions provide innovative ways to help patients manage their symptoms anywhere, anytime.

What evidence suggests that this trial's treatments could be effective for PTSD and cannabis use disorder?

This trial compares two digital therapeutic approaches for managing PTSD and cannabis use disorder. Research has shown that digital tools like the RISE Guide, one of the treatments in this trial, can help manage these issues by focusing on relaxation and stress management. This method uses cognitive behavioral techniques to reduce anxiety sensitivity, meaning individuals become less afraid of feeling anxious. Studies indicate that these techniques can lower stress and improve coping, reducing the risk of PTSD and substance use problems. The RISE Guide offers personalized reminders and support through a smartphone app, making it easy to use. By focusing on reducing stress without medication, it provides a promising option for those dealing with PTSD and cannabis use. Meanwhile, the Relaxation arm, another treatment option in this trial, involves using the "Breathe2Relax" app to manage stress through diaphragm breathing techniques. Participants will receive reminders to engage with this relaxation intervention.23678

Are You a Good Fit for This Trial?

This trial is for English-speaking women over 18 who have experienced a sexual assault within the last 72 hours and are seeking emergency care. They must use cannabis more than once weekly, have high anxiety sensitivity, own a smartphone with service for over a year, and be able to consent. Exclusions include living with the assailant, being an admitted patient or prisoner, cognitive impairments preventing informed consent, current pregnancy, no fixed address or prior enrollment.

Inclusion Criteria

Able to provide informed consent
Have a smartphone with continuous service >1 year
Report >1x/weekly cannabis use on a substance use screener
See 2 more

Exclusion Criteria

Prisoner
Previously enrolled
No sexual assault nurse examiner (SANE) examination
See 7 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive a digital therapeutic intervention targeting anxiety sensitivity and PTSD-CUD risk, including a 3-week cognitive behavioral intervention followed by 6 weeks of ecological momentary intervention

9 weeks

Follow-up

Participants are monitored for safety and effectiveness after treatment, with assessments of PTSD symptoms, anxiety, depression, and cannabis use

6 months

What Are the Treatments Tested in This Trial?

Interventions

  • Relaxation Control
  • RISE Guide
Trial Overview The study tests a new digital therapeutic called RISE Guide against Relaxation Control to prevent PTSD-CUD in women after sexual assault. It aims to evaluate user acceptability and effectiveness of these interventions in reducing PTSD-CUD risk among survivors presenting at emergency care sites.
How Is the Trial Designed?
2Treatment groups
Experimental Treatment
Active Control
Group I: RISE GuideExperimental Treatment1 Intervention
Group II: RelaxationActive Control1 Intervention

Relaxation Control is already approved in United States, European Union for the following indications:

🇺🇸
Approved in United States as Relaxation Control for:
🇪🇺
Approved in European Union as Relaxation Techniques for:

Find a Clinic Near You

Who Is Running the Clinical Trial?

University of Nevada, Las Vegas

Lead Sponsor

Trials
81
Recruited
14,700+

University of North Carolina, Chapel Hill

Collaborator

Trials
1,588
Recruited
4,364,000+

Published Research Related to This Trial

In a study of 150 participants with PTSD over one year, those using dispensary-obtained cannabis experienced a greater reduction in PTSD symptoms compared to those who did not use cannabis, suggesting potential efficacy of cannabis as a treatment.
Cannabis users were found to be 2.57 times more likely to no longer meet the criteria for PTSD by the end of the study, indicating a significant improvement in their condition compared to non-users.
The Long-Term, Prospective, Therapeutic Impact of Cannabis on Post-Traumatic Stress Disorder.Bonn-Miller, MO., Brunstetter, M., Simonian, A., et al.[2023]
This study will assess the relaxation effects of 360-degree nature videos on 36 military personnel diagnosed with PTSD, comparing the effects of viewing these videos on a head-mounted display versus a PC screen against a control condition of just listening to natural sounds.
The research aims to determine if the duration of the video (five vs. ten minutes) influences relaxation levels, providing foundational data for future trials on innovative PTSD treatments.
Nature videos for PTSD: protocol for a mixed-methods feasibility study.Knaust, T., Felnhofer, A., Kothgassner, OD., et al.[2022]
In a study of 23 subjects with panic disorder, diazepam was the only treatment that produced significant physiological changes, indicating its efficacy in reducing anxiety symptoms.
Relaxation therapy showed the largest improvements in self-reported anxiety and depression, suggesting it may be a beneficial approach for managing general anxiety in panic disorder, even though these changes were not statistically significant.
A controlled comparison of relaxation and diazepam in panic disorder.Taylor, CB., Kenigsberg, ML., Robinson, JM.[2013]

Citations

Cannabis in the management of PTSD: a systematic reviewThis results in lower stress levels and better patient coping, ultimately reducing remission rates [14],[16],[20]. Current systematic reviews [21]–[25] ...
Digital Therapeutics for PTSD and Cannabis Use DisorderThe RISE Guide treatment is unique because it focuses on digital therapeutic methods like relaxation techniques and stress management, which are non-drug ...
Effectiveness of treating post‐traumatic stress disorder in ...The primary outcome was PTSD severity; the secondary outcomes were loss of PTSD diagnosis, full remission of PTSD diagnosis and SUD severity. We ...
Post-Traumatic Stress Disorder - Summary of Evidence of ...A review of the clinical effectiveness and potential harms of clonidine for the treatment of adults with psychiatric conditions and symptoms as well as a review ...
Cannabis use and trauma-focused treatment for ...Specifically, data were pooled from four RCTs comparing Concurrent Treatment of PTSD and Substance Use Disorders. Using Prolonged Exposure (COPE ...
Cannabis use and posttraumatic stress disorder: prospective ...Strong prospective associations capturing within-person changes suggest that cannabis use is linked with greater severity of trauma-related intrusion symptoms ...
Clearing the Smoke on Cannabis: Regular Use and Mental ...Cannabis use is associated with poorer mental health outcomes in PTSD ... Post-traumatic stress disorder (PTSD) results from exposure to a traumatic ...
Impact of Cannabis Use on Treatment Outcomes among ...Cannabis use was not associated with adverse outcomes in end-of-treatment PTSD and primary substance use, suggesting independent pathways of change.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security